tebentafusp

Home
Ligands
tebentafusp

GtoPdb Ligand ID: 7378

Synonyms: IMCgp100 | Kimmtrak® | tebentafusp-tebn

tebentafusp is an approved drug (FDA & EMA (2022))

Comment: Tebentafusp (IMCgp100) is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3-4]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to restore immune surveillance and T-cell-directed killing of specific cancer cells.

References
1. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. (2014) ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother, 63 (5): 437-48. [PMID:24531387]
2. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK et al.. (2005) Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol, 23 (3): 349-54. [PMID:15723046]
3. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K et al.. (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med, 18 (6): 980-7. [PMID:22561687]
4. Martinez-Perez D, Viñal D, Solares I, Espinosa E, Feliu J. (2021) Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. Cancers (Basel), 13 (23). DOI: 10.3390/cancers13235968 [PMID:34885078]
5. Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O et al.. (2020) Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res, 26 (22): 5869-5878. [PMID:32816891]
6. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM et al.. (2021) Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med, 385 (13): 1196-1206. [PMID:34551229]

References

1. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. (2014)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Cancer Immunol Immunother, 63 (5): 437-48. [PMID:24531387]

2. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK et al.. (2005)
Directed evolution of human T-cell receptors with picomolar affinities by phage display.
Nat Biotechnol, 23 (3): 349-54. [PMID:15723046]

3. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K et al.. (2012)
Monoclonal TCR-redirected tumor cell killing.
Nat Med, 18 (6): 980-7. [PMID:22561687]

4. Martinez-Perez D, Viñal D, Solares I, Espinosa E, Feliu J. (2021)
Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.
Cancers (Basel), 13 (23). DOI: 10.3390/cancers13235968 [PMID:34885078]

5. Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O et al.. (2020)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Clin Cancer Res, 26 (22): 5869-5878. [PMID:32816891]

6. Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM et al.. (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med, 385 (13): 1196-1206. [PMID:34551229]